Insulin resistance and non-alcoholic fatty liver disease: a review of the pathophysiology and the potential targets for drug actions by Azeez, Taoreed Adegoke & Osundina, Morenike
J Med Sci, Volume 52, Number 4, 2020, October: 365-376
365*corresponding author: adegokegalaxy@yahoo.com
Journal of the Medical Sciences
(Berkala Ilmu Kedokteran)
Volume 52, Number 4, 2020; 365-376 
http://dx.doi.org/10.19106/JMedSci005204202010
Submitted : 2020-09-08  
Accepted   : 2020-09-23
Keywords: 
hepatic insulin resistance; 
athophysiology; 
treatment; 
potential new drugs; 
NAFLD;
Insulin resistance and non-alcoholic fatty liver disease: a 
review of the pathophysiology and the potential targets 
for drug actions
Taoreed Adegoke Azeez1*, Morenike Osundina2
1Endocrinology, Metabolism and Diabetes Unit, Department of Medicine, 2Gatroenterology & 
Hepatology Unit, Department of Medicine, University College Hospital, Ibadan, Nigeria.
ABSTRACT
Insulin resistance refers to the reduced physiological effects of insulin on 
various tissues. Insulin resistance has been implicated in the pathophysiology 
of non-alcoholic fatty liver disease (NAFLD), which is a spectrum of diseases 
ranging from hepatic steatosis on one end to steatohepatitis, liver cirrhosis 
and hepatocellular carcinoma on the other end. In most parts of the developed 
world, it is now the most commoncause of chronic liver disease and the most 
commonindication for liver transplantation. A similar findingis emerging in 
the developing world due to the rising prevalence of obesity and widespread 
adoption of Western lifestyles. Despite these epidemiological data, there 
are no universally approved medications for the treatment of NAFLD. The 
pathophysiological mechanisms of NAFLD essentially include adipose tissue 
insulin resistance, hepatic insulin resistance, inflammation and fibrosis. 
At the subcellular level, mitochondrial dysfunction, oxidative changes and 
endoplasmic reticulum dysfunction have been documented. Several drugs have 
been tested in vitro and in animal studies to target these pathophysiological 
mechanisms. Some are presently going through clinical trials, while others 
have already gone through clinical trials with variable results. Other potential 
target sites of drug development for the treatment of NAFLD are based on 
the complex pathophysiology of the disease. Insulin resistance plays an 
important role in the development of NAFLD. There are potential targets in 
the pathophysiology of NAFLD that can be explored in the development of 
medications for the disease.
INTRODUCTION
Insulin resistance is defined as 
a reduced physiological response to 
a given amount of insulin. It is the 
attenuated sensitivity of tissues to the 
biological effects of insulin.1 Insulin is a 
peptide hormone secreted by the β-cells 
of the pancreatic islets of Langerhans.2 
Its physiological roles are broadly 
divided into two, namely, metabolic and 
mitogenic effects. The metabolic effects 
include glucose disposal into the cells 
and the regulation of carbohydrate, 
lipid and protein metabolism, while the 
mitogenic effect refers to cell growth. 
The metabolic effects of insulin are 
most pronounced in the liver, muscle 
and adipose tissue. Whenever there is 
reduced sensitivity of peripheral tissues 
to insulin,pancreatic β-cells secrete 
supraphysiological amounts of insulin 
to overcome insulin resistance, causing 
hyperinsulinaemia.2
Insulin resistance is associated with 
a number of laboratory and clinical 
abnormalities that tend to cluster together 
in a clinical syndrome termed metabolic 
syndrome. These abnormalities 
include variable degrees of glucose 
intolerance, dyslipidemia, visceral 
obesity and elevated blood pressure.1 
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Other documented disorders include 
cardiovascular disease, fatty liver disease, 
hyperuricaemia, cancers, polycystic 
ovarian syndrome and obstructive 
sleep apnoea. The pathophysiological 
mechanisms underlying metabolic 
syndrome include chronic subclinical 
inflammation, enhanced coagulability, 
haemodynamic dysfunction and 
endothelial dysfunction.2
Insulin resistance in the peripheral 
tissue, especially the adipose tissue, leads 
to enhanced lipolysis and increased 
flux of free fatty acids from the adipose 
tissue into the liver. The liver uses free 
fatty acids to synthesize triglycerides, 
which are incorporated into very low 
density lipoproteins (VLDL).3 When 
the physiological machinery for these 
synthetic processes is overwhelmed, 
fatty liver disease develops. With 
increasing levels of liver damage, non-
alcoholic fatty liver disease may progress 
to steatohepatitis, fibrosis, liver cirrhosis 
and sometimes liver cancer.
Nonalcoholic fatty liver disease 
(NAFLD) is characterized by 
macrovascular steatosis in at least 
5% of hepatocytes, and other causes, 
such as alcohol and drugs, must have 
been ruled out.4 It is now the leading 
cause of liver cirrhosis globally, yet 
the pharmacotherapeutic options for 
the disease are limited.5 The global 
prevalence of NAFLD is approximately 
25%.5 The prevalence is highest in 
developed countries and is rising 
in developing countries due to the 
increasing prevalence of obesity and 
adoption of Western lifestyles. The 
presence of fibrosis on histology is 
associated with increased clinical 
morbidity and mortality. Approximately 
1-5% of this cohort with fibrosis tends to 
develop liver cancer.5 Ultrasonography is 
the noninvasive diagnostic approach of 
choice, while liver biopsy for histologic 
examination remains a valuable tool in 
confirming fibrosis.4
The central approach in the 
management of NAFLD involves 
lifestyle and cardiovascular risk 
factor modifications such as dietary 
management, weight loss, control of 
dyslipidemia, stopping smoking and 
engaging in adequate physical activity.6 
However, studies have shown that 
lifestyle modifications alone are often 
not enough to regress or prevent the 
progression of the disease.4 Drugs such as 
vitamin E and pioglitazone, a peroxisome 
proliferator-activator receptor gamma 
(PPAR-γ) agonist, have been studied in 
clinical trials on pharmacotherapy of 
NAFLD, but the results are conflicting, 
and most guidelines have refrained from 
recommending these medications.7
Therefore, pharmacotherapy for 
NAFLD is a rapidly evolving field, and 
many studies are ongoing to identify 
potential target sites for drug action. 
Some drugs, such asobeticholic acid (a 
farnesoid X receptor agonist), are already 
undergoing clinical trials, but there is 
still a need to develop more drugs, and 
a deep understanding of the disease will 
play an important role in achieving this.3 
This review article aimed to expatiate 
the pathophysiological relationships 
between insulin resistance and NAFLD 
and to highlight the potential sites of 
target for pharmacotherapy to alleviate 
the burden of the disease.
DISCUSSION
Insulin Physiology
Overview of insulin as a biomolecule
Insulin is a polypeptide hormone 
made up of 51 amino acids and is coded 
in the short arm of chromosome 11.7 
It is made up of two chains, anα chain 
comprising 21 amino acids and a β chain 
comprising 30 amino acids. The two 
chains are connected by two disulfide 
bonds. Messenger ribonucleic acid 
(mRNA) transcribed from the insulin 
gene is translated as preproinsulin on 
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the ribosomes of rough endoplasmic 
reticulum. Pre-proinsulin is made up of 
the α chain, β chain, signal peptide and 
connecting peptide (C-peptide). Removal 
of the signal peptide from preproinsulin 
leads to the formation of proinsulin in 
the endoplasmic reticulum. Proinsulin 
is converted into insulin and C-peptide 
and is later packaged into secretory 
granules, where they are secreted into 
the circulation in equimolar amounts.
Insulin secretion
Glucose-mediated insulin release 
is biphasic. It is made up of an initial 
rapid release followed by a less intense 
and more sustained release.8 Glucose 
enters pancreatic β-cells via a non-
insulin-mediated mechanism through 
glucose transporter-2 (GLUT-2). It is 
then phosphorylated to glucose-6-
phosphate by glucokinase. This process 
progresses to the synthesis of adenosine 
triphosphate (ATP). Increased ATP/ADP 
ratio causes opening of membrane-
bound ATP-sensitive potassium (KATP) 
channels and influx of potassium ions. 
Ultimately, this leads to thedepolarization 
of the membraneandthe opening of 
voltage-gated calcium channels. Influx 
of calcium ions leads to pulsatile insulin 
secretion.9
There are other documented 
mechanisms by which insulin is secreted, 
especially the second phase of insulin 
secretion. These include activation of 
protein kinase A and protein kinase C as 
well as the stimulation of adenylyl cyclase 
and phospholipase.8 These mechanisms 
are regulated by incretin hormones 
such as glucagon-like peptide 1 (GLP-1) 
and glucose-dependent insulinotropic 
peptide (GIP).
Factors that stimulate the release of 
insulin are termed insulin secretagogues. 
They are divided into nutrient and non-
nutrient secretagogues.2 Examples of 
nutrient secretagogues are glucose and 
fructose, and examples of non-nutrient 
secretagogues are neurohormonal 
factors such as the cholinergic and 
adrenergic neural pathways and peptide 
hormones such as incretin hormones.8
Cholinergic stimulation of the 
muscarinic receptors of pancreatic β-cells 
leads to the activation of phospholipase 
C and protein kinase C and eventual 
mobilization of intracellular calcium 
to enhance insulin secretion.2 This 
sometimes occurs on sighting, tasting or 
chewing food, a phenomenon referred to 
as the cephalic phase of insulin secretion. 
During stress and exercise, activation 
of α-2 adrenergic receptors leads to 
inhibition of insulin release. The amino 
acids arginine, L-ornithine and leucine 
are also known to behave like insulin 
secretagogues.2
Insulin action
The physiological effects of insulin 
occur when it binds to its specific receptor. 
The insulin receptor is a heterotetramer 
made up of 2α and 2β glycoprotein 
subunits and is coded by a gene on the 
short arm of chromosome 19.10 The α 
subunit is extracellular, whereas the β 
subunit is intracellular. Insulin binds to 
the extracellular subunit, producing a 
conformational change in the receptor, 
thereby allowing ATP to bind to the β 
intracellular subunit. The β subunit is 
phosphorylated, and it acquires tyrosine 
kinase ability. This phosphorylates 
some protein molecules called insulin 
responsive substrate (IRS).
The phosphorylated IRS proteins 
bind other proteins generally called src-
homology-2 domain proteins (SH2).11 
Functionally, SH2 proteins are divided 
into two, namely, enzymatic SH2 
(examples are phosphatidylinositol-
3-kinase and phosphotyrosine 
phosphatase) and non-enzymatic SH2 
(an example is an adaptor protein 
called Grb 2). Phosphatidylinositol-
3-kinase phosphorylates some serine 
and threonine kinases, such as Akt/
protein kinase B and protein kinase C, 
which promote the metabolic actions of 
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insulin. These metabolic actions include 
translocation of glucose transporter 
(GLUT) to the cell membrane, 
glycogenesis, lipogenesis, protein 
synthesis and anti-lipolysis.12 Grb2, on 
the other hand, connects IRS-1 to the 
RAS (rat sarcoma protein) pathway, 
which mediates the mitogenic effects of 
insulin.10
Pathophysiology of Insulin Resistance
Insulin action is influenced by other 
hormones. Hormones, often referred 
to as counterregulatory hormones, 
such as glucagon, glucocorticoids, 
catecholamines and growth hormone, 
dictate metabolic activities in the fasting 
state and oppose the physiological 
actions of insulin. Any pathology 
leading to excessive production of 
these hormones can lead to insulin 
resistance. However, most individuals 
with insulin resistance do not have 
abnormalities with counterregulatory 
hormones.2 Insulin resistance is mostly a 
cellular problem that occurs as a result 
of defects in normal signaling.2 The 
pathophysiological impact of insulin 
resistance varies across different tissues.
Hepatic insulin resistance
A large portion of glucose absorbed 
from digested carbohydrates is disposed 
into hepatocytes, and the process is 
independent of insulin.13 In the fed 
state, carbohydrate metabolism in the 
liver rapidly changes from glucose 
synthesis (gluconeogenesis) to glycogen 
synthesis (glycogenesis) and storage.14 
This metabolic transition is under 
the regulation of neurohormonal 
mechanisms. For this transition to 
occur, there is a need to activate the 
enzyme glycogen synthase. Insulin 
activates this enzyme and makes hepatic 
glycogenesis possible in the postprandial 
state. Evidence for this role of insulin 
is seen in type 1 diabetes patients in 
whom glycogenesis is markedly reduced 
compared with controls after eating a 
mixed meal due to insulin deficiency.14 
In the presence of insulin, ketogenesis 
is inhibited. The mitogenic effects of 
insulin on hepatocytes are mediated 
by increased synthesis of insulin-like 
growth factor-1 (IGF-1).
Hepatic insulin resistance is 
characterized by enhanced hepatic 
glucose output though gluconeogenesis. 
There is also pronounced abnormality 
of lipoprotein metabolism in insulin-
resistant states. Insulin resistance in 
adipose tissue causes increased lipolysis 
and the release of large amounts of free 
fatty acids into circulation, which are 
trafficked to the liver. This increased fatty 
acid flux to the liver increases triglyceride 
synthesis in hepatocytes. Physiologically, 
triglycerides are supposed to be 
incorporated into VLDL, which are 
released into the circulation. However, 
hepatic insulin resistance reduces VLDL 
production, and triglycerides accumulate 
in the liver, causing steatosis.2 Moreover, 
insulin-resistant adipose tissue releases 
proinflammatory cytokines such as 
tumor necrosis factor-1 (TNF-1), which 
act on hepatocytes to produce C-reactive 
protein, fibrinogen and plasminogen 
activator inhibitor-1 (PAI-1), which can 
be assayed as markers of hepatic insulin 
resistance.15
Adipose insulin resistance
The main roles of insulin in adipose 
tissue are glucose influx into adipocytes, 
stimulation of lipogenesis and inhibition 
of lipolysis. In the postprandial state, 
glucose enters adipocytes via GLUT 4. 
This process is dependent on insulin.13 
In patients with type 2 diabetes, where 
insulin resistance is significantly 
high, downstream signaling following 
the action of insulin on its receptor 
is impaired.13 There is reduced gene 
expression of IRS-1, and the AKt/PKB 
pathway is dysregulated. This implies 
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reduced translocation of GLUT4 into the 
adipocyte membrane, which leads to 
reduced glucose disposal into adipose 
tissue.
The entry of glucose into adipocytes 
affects lipid metabolism by activating 
the carbohydrate response element 
binding protein (ChREBP).16 ChREBP is 
involved in the synthesis of fatty acid 
esters that enhance glucose tolerance. 
Adipose tissue secretes certain humoral 
molecules with varying physiological 
roles. These adipocytokines, namely, 
leptin, resistin and adiponectin, affect 
insulin sensitivity. Adiponectin enhances 
insulin sensitivity, whereas resistin 
and leptin are associated with insulin 
resistance.17 Mice with adiponectin gene 
knockoutare more prone to hepatic 
steatosis.18
Pathophysiology of Non-alcoholic 
Fatty Liver Disease.
NAFLD is currently the most common 
cause of end-stage liver disease and 
the most common common reason for 
liver transplantation.19 It is a diagnosis 
of exclusion. There are two types of 
hepatic steatosis, namely, microsteatosis 
and macrosteatosis. Other causes of 
macrosteatosis, apart from NAFLD, 
are alcohol, drugs such as steroids, 
autoimmune hepatitis, hepatitis C and 
parenteral nutrition. Common causes of 
microsteatosis include Reye syndrome, 
acute fatty liver of pregnancy, inborn 
errors of metabolism and drugs such 
as valproate. All these causes of hepatic 
steatosis need to be excluded before a 
diagnosis of NAFLD is made.
NAFLD is a metabolic disorder and 
is a result of the interplay between 
hormonal, dietary and genetic factors.19 
Researchers working on genome-
wide association studies (GWAS) have 
documented some promising candidate 
genes that serve as the underlying 
genetic factors for NAFLD.20 These 
genetic factors appear to predispose 
obese populations with insulin 
resistance to NAFLD. Obesity is the link 
between insulin resistance and NAFLD. 
Insulin resistance and consequent 
hyperinsulinaemia are central to the 
pathophysiology of NAFLD. In fact, some 
authors have documented that NAFLD 
is essentially a hepatic component of 
insulin resistance syndrome.21
Hepatic steatosis must be present 
before a diagnosis of NAFLD is 
considered. The pathogenic mechanisms 
of hepatic steatosis include consumption 
of food high in fats, increased lipolysis 
due to adipose tissue insulin resistance, 
reduced β-oxidation of fatty acids, 
increased hepatic lipogenesis and 
decreased VLDL export from the liver 
due to hepatic insulin resistance.20 
The molecular biology behind these 
mechanisms is still not fully understood, 
but research is ongoing to elucidate 
the biochemical processes underlying 
hepatic steatosis.21
A proposed hypothesis is that 
inflammatory cytokines from adipose 
tissue as a result of adipose tissue insulin 
resistance initiate the processes leading 
to NAFLD.22 However, the factors that 
initiate inflammation in adipose tissue 
are not known. Hypoxia and necrosis 
of rapidly enlarging adipocytes have 
been suggested by some researchers.22 
Inflammatory cytokines such as 
tumor necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6) released by adipose 
tissue macrophages have been reported 
to regulate insulin resistance in the 
liver.23 Additionally, adipocytes secrete 
adipokines such as adiponectin, which 
has been reported to regulate β-oxidation 
of fatty acids in the liver through AMP-
activated protein kinase and acetyl-CoA 
carboxylase signaling.24
Simple deposition of fats in 
hepatocytes progresses to a varying 
degree of the NAFLD spectrum due to 
the cellular mechanisms of oxidative 
stress, lipotoxicity, endoplasmic 
reticulum stress and mitochondrial 
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dysfunction.20 Increased  flux  of  fatty 
acids to hepatocytes is due to adipose 
tissue insulin resistance and increased 
lipolysis in adipocytes. The metabolism 
of fatty acids in the hepatic mitochondria 
and peroxisomes leads to increased 
generation of reactive oxygen species, 
reactive nitrogen species and lipid 
peroxidation, hence enhancing oxidative 
stress in hepatocytes.25 Accumulation of 
saturated fatty acids, free cholesterol and 
lipid intermediates in hepatocytes has 
been found to produce lipotoxic stress 
to the mitochondria and endoplasmic 
reticulum of hepatocytes, leading to 
cellular death and tissue inflammation.26 
There is also reduced activity of the 
enzyme complex of the electron 
transport chain causing mitochondrial 
dysfunction and hence reduced 
β-oxidation and accumulation of fatty 
acids. Endoplasmic reticulum stress is 
indicated by the reduced capacity and 
efficiency in protein folding and repair 
despite the increased demand for it 
due to the cellular stress of NAFLD.20 
The summary of the pathophysiology of 
NAFLD is illustrated in FIGURE 1.
FIGURE 1. Pathophysiology of non-alcoholic fatty liver disease
Target Sites of Drug Action in NAFLD.
Presently, there are no universally 
accepted pharmacotherapeutic protocols 
for NAFLD. Several clinical trials have 
been performed, yet no approved 
drug for the treatment of NAFLD is 
universally accepted.27 Although lifestyle 
modifications such as weight loss, dietary 
management and exercise have been 
shown to be helpful, they are difficult 
to adopt for a long time.28 Therapeutic 
failure is therefore not uncommon due 
to the inability to sustain weight loss 
for a long period. There is therefore a 
need to develop drugs that will target 
strategic points in the pathophysiology 
of NAFLD.A summary of the drugs that 
can be used in NAFLD is summarized in 
TABLE 1 and 2.
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TABLE 1. Drugs that have been tried in the management of non-alcoholic 
liver fatty liver disease
Drug Mechanism of action Outcome
Orlistat Pancreatic lipase inhibitor Not beneficial
Rimonabant Endocannabinoid receptor agonist Withdrawn
Metformin Hepatic insulin sensitizer Not beneficial
Thiazolidinediones Adipose tissue insulin sensitizer Beneficial
Probucol Serum lipid lowering/anioxidant Not beneficial
Vitamin E Antioxidant Beneficial
Silymarin Antioxidant Beneficial
Pentoxifylline Antioxidant Beneficial
Probiotics Alteration of gut microbiota Beneficial
TABLE 2. Potential drugs in the management of non-alcoholic liver 
fatty liver disease
Drug Mechanism of action
Thyroid hormones Hepatic lipogenesis inhibitor
DPP-4 inhibitors Hepatic insulin senstizer
GLP-1 agonists Hepatic insulin senstizer
Chenodeoxycholic acid, obeticholic acid Farnesoid X receptor agonist




Targeting absorption of fat
A high-fat diet has been implicated 
in the pathophysiology of NAFLD. 
Pancreatic lipase inhibitors such as 
orlistat inhibit the absorption of fats. In 
a randomized controlled trial, however, 
the use of orlistat was not associated 
with any histological improvement.29 
Targeting intrahepatic lipogenesis 
may be more beneficial than merely 
inhibiting ingested fat absorption.
Targeting hepatic fat storage
Activation of endocannabinoid 
receptors (CB1) widely expressed 
in hepatocytes has been associated 
with hepatic steatosis. It is therefore 
thought that CB1 antagonists will 
reduce hepatic steatosis. Truly, a CB-1 
antagonist, Rimonabant, was approved 
for the treatment of hepatic steatosis 
as well as obesity.30 However, it was 
withdrawn due to its neuropsychiatric 
side effects. Developing drugs that can 
specifically target hepatic CB-1 receptors 
without activating the central nervous 
endocannabinoid system may be 
extremely useful in treating NAFLD.
Thyroid hormone analogues have also 
been suggested to have the capability of 
reducing hepatic storage and hence may 
play a role in the treatment of NAFLD. 
Animal studies have shown that there are 
specific nuclear receptors in hepatocytes 
that thyroid hormones interact with, and 
it is through that this interaction is able 
to inhibit hepatocyte lipogenesis.
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Targeting hepatic insulin resistance
Metformin improves insulin 
sensitivity in the liver. It reduces hepatic 
glucose output, hepatic expression of 
TNF-α and intrahepatic lipogenesis.27 
Metformin is well tolerated, but studies 
have not shown its effectiveness 
in treating NAFLD. A  randomized 
controlled trial comparing metformin 
with vitamin  E  in the treatment  of  NAFLD 
did not show a significant reduction 
in transaminases or improvement in 
histology in the metformin arm.31
Incretin-based antidiabetic 
medications,  dipeptidyl  peptidase-4 
(DPP-4) inhibitors and glucagon-like 
peptide-1 (GLP-1) agonists, have been 
shown to improve hepatic insulin 
sensitivity. They have been tried in 
animal studies and non-randomized 
human studies to treat NAFLD and 
have been found to be effective, but 
randomized clinical trials are being 
awaited to substantiate the clinical 
benefits of these drugs in the treatment 
of NAFLD.
There are some receptors in 
hepatocytes, and most other tissues in the 
body are called  farnesoid X receptors. 
Activation of these receptors is known 
to improve insulin sensitivity in the 
liver.27 Agonists of these receptors have 
been demonstrated in animal studies 
to reduce transaminases and improve 
histology in animal models of NAFLD.27 
Human studies on these pharmacologic 
agents are still being awaited. An 
example of farnesoid X receptor agonists 
is chenodeoxycholic acid.
Targeting adipose tissue insulin resistance
Thiazolidinediones (glitazones) 
are peroxisome proliferator-activator 
receptor-γ (PPAR-γ) agonists. 
Pioglitazone has been demonstrated 
to be effective for treating NAFLD in 
randomized clinical trials; however, the 
side effects of drugs such as weight gain, 
heart failure and osteoporosis are of 
grave concern.32 The beneficial effects of 
pioglitazone were reversed by stopping 
it, implying that it has to be taken for a 
long period of time. Using it for this long, 
however, may predispose the patients to 
the side effects of pioglitazone.
Targeting serum lipids
The rationale for targeting serum 
lipids is that it is believed that lowering 
serum lipids will reduce hepatic 
accumulation of fatty acids and 
triglycerides. Studies have shown that 
lipid-lowering agents, namely, statins, 
fibrates and ezetimibe, are well tolerated 
and efficacious in the treatment of 
hepatic steatosis.33 Despite these findings, 
multicentric randomized controlled 
trials for a long duration are lacking to 
substantiate the effects of lipid lowering 
agents on hepatic steatosis. In addition 
to its lipid-lowering effects, probucol 
also has a significant antioxidant effect, 
but studies are insufficient to support 
its beneficial roles in the treatment of 
NAFLD.
Targeting oxidation pathways
In the pathogenesis of fatty liver, 
oxidation of fatty acids leads to 
cellular damage and activation of pro-
inflammatory cytokines.27 This is the 
main mechanism by which hepatic 
steatosis progresses to steatohepatitis, 
then to liver cirrhosis and finally 
hepatocellular carcinoma. Vitamin C and 
vitamin E have been used as antioxidants 
in the treatment of NAFLD. Vitamin E 
has been shown to improve histology 
and reduce aminotransferases in many 
trials.31 Silymarin, which is an extract of 
milk thistle (Silybummarianum), has been 
shown to possess antioxidative effects 
and anti-inflammatory properties, and 
some studies have demonstrated its 
usefulness in NAFLD, especially when 
combined with vitamin E.34
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Other antioxidants that have been 
tried in NAFLD with variable effects 
include quercetin and betaine. In 
addition, pentoxifylline has been found 
to protect against lipid oxidation, one 
of the mechanisms underlying the 
pathogenesis of NAFLD.27 Randomized 
controlled trials have reported the 
efficacy of pentoxifylline in improving 
the histology seen in NAFLD.
Targeting gut microbiota
Interfering with the gut microbiota 
using probiotics has been found to be 
beneficial in reducing insulin resistance, 
especially in animal studies. Some 
studies have shown beneficial effects of 
probiotics in the treatment of NAFLD, 
but these studies are scant.35
Targeting inflammatory cytokines
Clearly, inflammation plays a crucial 
role in the development and progression 
of NAFLD. In animal studies, the use of 
antibodies against TNF-α (infliximab) 
has been reported to improve the 
histologic features of NAFLD.36 These 
findings will still need to be replicated 
in humans through randomized clinical 




system (RAAS) has been implicated 
in hepatic fibrosis that characterizes 
the progression of NAFLD.37 Animal 
studies have demonstrated that the use 
of valsartan, which is an angiotensin 
receptor blocker, can improve the 
histological changes seen in NAFLD.37 The 
role of RAAS inhibition against hepatic 
fibrosis in humans is still a potential area 
for future research.
Targeting apoptosis and necro-
inflammation.
Apoptosis and necro-inflammation 
are involved in the progression of hepatic 
steatosis to steatohepatitis, cirrhosis 
and hepatocellular cancer. Caspases 
are proteases that break down essential 
proteins in the cell during programmed 
cell death, and their roles in NAFLD 
have been reported in the literature. 
Drugs inhibiting caspases, designed for 
the treatment of NAFLD, are in various 
stages of drug development trials.
CONCLUSION
Insulin resistance is the hallmark 
of many chronic diseases with high 
cardiovascular risk. Insulin resistance 
syndrome refers to a constellation of 
cardiovascular risk factors, and non-
alcoholic liver disease is considered 
the hepatic manifestation of the 
syndrome. Nonalcoholic liver disease 
is a diagnosis of exclusion, and it is a 
spectrum of hepatic diseases ranging 
from simple hepatic steatosis on one end 
and hepatocellular carcinoma on the 
other end. The prevalence is very high 
globally and is the most common cause 
of cirrhosis in developed nations. The 
prevalence is also rapidly rising in low-
and middle-income countries due to the 
obesity epidemic and westernization in 
those settings.
The review has emphasized the 
limitations of the presently available 
therapy to diseases that are now of 
public health significance. In view of this, 
potential targets for the development of 
new drugs based on the pathophysiology 
of the disease have been identified. 
There is a need to carry out more in 
vitro studies to design these drugs and 
clinical trials to test the clinical safety 
and acceptability of such drugs.
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